Brief Report: Does Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
15 04 2023
15 04 2023
Historique:
received:
16
08
2022
accepted:
19
12
2022
pubmed:
4
1
2023
medline:
14
3
2023
entrez:
3
1
2023
Statut:
ppublish
Résumé
Increasing numbers of women living with HIV transition through menopause. It is unclear whether this transition has an impact on treatment adherence, viral suppression, psychiatric comorbidities, or drug use. We aimed at examining adherence and viral suppression during the perimenopausal period and explored the influence of psychiatric comorbidities and active injection drug use (IDU). Retrospective Swiss HIV Cohort Study analysis from January 2010 to December 2018. We explored perimenopausal and postmenopausal trends of viral blips, low-level viremia, viral failure, adherence, psychiatric comorbidities, and IDU using interrupted time series models. Rates of depression and psychiatric care increased during perimenopause before decreasing afterward. Negative treatment outcomes such as viral blips, low-level viremia, viral failure, and low adherence steadily declined while transitioning through menopause-this was also true for subgroups of women with depression, psychiatric treatment, and active IDU. Increased rates of depression and psychiatric care while transitioning through menopause do not result in lower rates of adherence or viral suppression in women living with HIV in Switzerland.
Sections du résumé
BACKGROUND
Increasing numbers of women living with HIV transition through menopause. It is unclear whether this transition has an impact on treatment adherence, viral suppression, psychiatric comorbidities, or drug use. We aimed at examining adherence and viral suppression during the perimenopausal period and explored the influence of psychiatric comorbidities and active injection drug use (IDU).
SETTING
Retrospective Swiss HIV Cohort Study analysis from January 2010 to December 2018.
METHODS
We explored perimenopausal and postmenopausal trends of viral blips, low-level viremia, viral failure, adherence, psychiatric comorbidities, and IDU using interrupted time series models.
RESULTS
Rates of depression and psychiatric care increased during perimenopause before decreasing afterward. Negative treatment outcomes such as viral blips, low-level viremia, viral failure, and low adherence steadily declined while transitioning through menopause-this was also true for subgroups of women with depression, psychiatric treatment, and active IDU.
CONCLUSIONS
Increased rates of depression and psychiatric care while transitioning through menopause do not result in lower rates of adherence or viral suppression in women living with HIV in Switzerland.
Identifiants
pubmed: 36595226
doi: 10.1097/QAI.0000000000003158
pii: 00126334-990000000-00177
pmc: PMC9988224
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-404Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
None of the authors has declared a possible conflict of interest related to this study. A.H.'s institution has received travel grants, congress and advisory fees from MSD, ViiV, and Gilead, unrelated to this work. B.B. Flury has undertaken Advisory Boards or ad hoc consultancy for Merck/MSD, Melinta/Menarini, Shionogi, and Pfizer, and has received research grants from Melinta/Menarini unrelated to this work. K.E.A.D.'s institution has received research funding unrelated to this publication from Gilead and offered expert testimony for MSD. P.T.'s institution has received grants, advisory fees, and educational grants from Gilead, MSD, and ViiV outside the submitted work. K.A.-P.’s institution has received travel grants and advisory fees from MSD, Gilead, and ViiV healthcare unrelated to this work. I.A.A. is supported by the ProMedica Foundation.
Références
Hachfeld A, Atkinson A, Stute P, et al. Women with HIV transitioning through menopause: insights from the Swiss HIV cohort study (SHCS). HIV Med. 2022;23:417–425.
Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810–818.
Smit M, Cassidy R, Cozzi-Lepri A, et al. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017;12:e0186638.
Van Ommen CE, King EM, Murray MCM. Age at menopause in women living with HIV: a systematic review. Menopause. 2021;28:1428–1436.
Ferreira CE, Pinto-Neto AM, Conde DM, et al. Menopause symptoms in women infected with HIV: Prevalence and associated factors. Gynecol Endocrinol. 2007;23:198–205.
Tariq S. Positive tRansItions through Menopause (PRIME). Institute for Global Health; 2018. Available at: https://www.ucl.ac.uk/global-health/research/a-z/PRIME .
Looby SE. Symptoms of menopause or symptoms of HIV? Untangling the knot. Menopause. 2018;25:728–730.
Maki PM, Rubin LH, Cohen M, et al. Depressive symptoms are increased in the early perimenopausal stage in ethnically diverse human immunodeficiency virus–infected and human immunodeficiency virus–uninfected women. Menopause. 2012;19:1215–1223.
Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63:385–390.
Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med. 2011;41:1879–1888.
Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 1999–2002;30:401–409.
Relf MV, Pan W, Edmonds A, et al. Discrimination, medical distrust, stigma, depressive symptoms, antiretroviral medication adherence, engagement in care, and quality of life among women living with hiv in north carolina: a mediated structural equation model. J Acquir Immune Defic Syndr. 2019;81:328–335.
Scherrer AU, Traytel A, Braun DL, et al. Cohort profile update: The Swiss HIV cohort study (SHCS). Int J Epidemiol. 2022;51:33–34j.
R Core Team, R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. 2019. Available at: http://www.R-project.org/
Tasker C, Ding J, Schmolke M, et al. 17β-estradiol protects primary macrophages against hiv infection through induction of interferon-alpha. Viral Immunol. 2014;27:140–150.
Rodriguez-Garcia M, Biswas N, Patel MV, et al. Estradiol reduces susceptibility of CD4+ T cells and macrophages to HIV-infection. PLoS One. 2013;8:e62069.
Szotek EL, Narasipura SD, Al-Harthi L. 17β-estradiol inhibits HIV-1 by inducing a complex formation between β-catenin and estrogen receptor on the HIV promoter to suppress HIV transcription. Virology. 2013;443:375–383.
Das B, Dobrowolski C, Luttge B, et al. Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proc Natl Acad Sci U S A. 2018;115:E7795–E7804.
Gianella S, Rawlings SA, Nakazawa M, et al. Sex differences in HIV Persistence and Reservoir Size during Aging. Clin Infect Dis. 2021:ciab873.
Alejos B, Suárez-García I, Bernardino JI, et al. Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort. Antivir Ther. 2020;25:335–340.
Calvet GA, Velasque L, Luz PM, et al. Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: A Cohort Study from Rio de Janeiro, Brazil. PLoS One. 2014;9:e89299.
Patterson KB, Cohn SE, Uyanik J, et al. Treatment responses in antiretroviral treatment–naive premenopausal and postmenopausal HIV‐1–infected women: An analysis from AIDS clinical trials group studies. Clin Infect Dis. 2009;49:473–476.
Okhai H, Tariq S, Burns F, et al. Associations of menopausal age with virological outcomes and engagement in care among women living with HIV in the UK. HIV Res Clin Pract. 2020;21:174–181.
Ghidei L, Simone MJ, Salow MJ, et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging. 2013;30:809–819.
Kiplagat J, Mwangi A, Keter A, et al. Retention in care among older adults living with HIV in western Kenya: A retrospective observational cohort study. PLoS One. 2018;13:e0194047.
Solomon D, Sabin CA, Burns F, et al. The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIV. AIDS Care. 2021;33:101–108.
Duff PK, Money DM, Ogilvie GS, et al. Severe menopausal symptoms associated with reduced adherence to antiretroviral therapy among perimenopausal and menopausal women living with HIV in Metro Vancouver. Menopause. 2018;25:531–537.
Cutimanco-Pacheco V, Arriola-Montenegro J, Mezones-Holguin E, et al. Menopausal symptoms are associated with non-adherence to highly active antiretroviral therapy in human immunodeficiency virus-infected middle-aged women. Climacteric. 2020;23:229–236.
Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15:105–114.
El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019;26:1213–1227.
Virologic Failure. NIH [Internet]. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/virologic-failure